Cybin Inc. Announces Q2 2025 Financial Results Conference Call and Provides Business Update

Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) will host a conference call and webcast at 8 a.m. ET on Thursday, November 13, 2025, to provide a business update and report financial results for its second quarter ended September 30, 2025. The company, which describes itself as a late-stage breakthrough neuropsychiatry company, is focused on revolutionizing mental healthcare through the development of innovative treatment options for mental health conditions.

The timing of this financial results announcement comes as Cybin continues to advance its clinical pipeline, including CYB003, a proprietary deuterated psilocin analog currently in Phase 3 studies for the adjunctive treatment of major depressive disorder. This investigational treatment has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, potentially accelerating its development timeline and regulatory review process. The company is also developing CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder.

Cybin's approach to mental health treatment represents a significant shift in the neuropsychiatry landscape, focusing on developing novel drugs that provide effective and durable results for patients suffering from mental health conditions. The company maintains a research pipeline of investigational, 5-HT-receptor focused compounds, indicating a comprehensive approach to addressing the large unmet need in mental healthcare. Additional information about the company's developments can be found in their newsroom at https://ibn.fm/CYBN.

The implications of Cybin's progress extend beyond the company itself to the broader mental health treatment industry and the millions of patients worldwide who struggle with conditions like major depressive disorder and generalized anxiety disorder. With traditional treatments often providing limited relief or significant side effects, the development of breakthrough therapies could represent a paradigm shift in how mental health conditions are managed. The company's focus on deuterated compounds suggests an approach that may improve pharmacokinetic properties and therapeutic outcomes compared to existing treatments.

For investors and the healthcare industry, Cybin's quarterly results and business updates provide crucial insights into the company's financial health and clinical progress. The neuropsychiatry sector has seen growing interest from both pharmaceutical companies and investors, particularly as mental health awareness increases globally and regulatory pathways for novel treatments become more defined. The company's operational presence across Canada, the United States, the United Kingdom, and Ireland positions it to navigate multiple regulatory environments and potentially access diverse patient populations for clinical development and future commercialization.

The upcoming conference call will likely address not only financial performance but also important milestones in the company's clinical development programs, regulatory interactions, and strategic initiatives. As mental health continues to be recognized as a critical component of overall healthcare, companies like Cybin that are developing innovative treatment approaches could play an increasingly important role in addressing what the World Health Organization has identified as a growing global health concern.